March 16, 2017

Researchers discover new test that could change the diagnosis and treatment of prostate cancer

Dr. Paul Boutros

Genetic tests are being used more commonly in the diagnosis of many types of cancer. However, there currently isn’t a highly accurate test that can identify men with aggressive forms of prostate cancer, making it more difficult to choose the most appropriate course of treatment.

Continue reading – Researchers discover new test that could change the diagnosis and treatment of prostate cancer

January 10, 2017

New prognostic test for prostate cancer now closer to clinical use

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men, but there is still no one-size-fits-all strategy for treating the disease. Currently it is difficult to choose exactly the right type and amount of treatment for each individual because it is hard to accurately assess how aggressive the cancer is. Researchers are now a step closer to bringing a powerful new prognostic tool into clinical use.

Continue reading – New prognostic test for prostate cancer now closer to clinical use

January 9, 2017

Scientists identify DNA signature linked to prostate cancer severity

Findings published in renowned journal Nature

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.

Continue reading – Scientists identify DNA signature linked to prostate cancer severity

October 19, 2016

From our Annual Report: Personalizing prostate cancer treatment

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men and while it has been the focus of extensive research, an estimated 4,000 Canadians die of the disease each year. That is why six years ago Dr. Paul Boutros and Dr. Rob Bristow set out to sequence the normal and diseased tissue of 350 patients and learn from a clinical perspective how genomic information can be used to guide better treatment.

Continue reading – From our Annual Report: Personalizing prostate cancer treatment

September 15, 2016

Dr. Paul Boutros talks genomics and prostate cancer research

Dr. Paul Boutros, Principal Investigator in Informatics and Bio-computing at OICR, spoke to our partners at Prostate Cancer Canada/Movember Canada about the role of genomics and informatics in prostate cancer research. Boutros also spoke about the CPC-GENE project – the largest study of prostate cancer genomics in the world.

September 15, 2016

Canadian government makes big investment in big data research

OICR's server room

On September 13 the Government of Canada, through Genome Canada, made a $4 million investment in Canadian big data research to help improve real world challenges such as infectious disease outbreaks, managing food crops and combating cancer.

Of the 16 projects funded across Canada, three are based at OICR. Led by OICR Principal Investigators Drs. Paul Boutros, Vincent Ferretti, Jared Simpson and Lincoln Stein (Stein is also OICR’s Interim Scientific Director and leader of the Institute’s Informatics and Biocomputing Program), the projects are developing ways to make genomics and health data more manageable, securely accessible and easily understood. Together these projects will help to facilitate cancer research and assist in the adoption of more precision medicine. As well, they have applications in other fields of genomics research beyond cancer, such as agriculture and energy.

Continue reading – Canadian government makes big investment in big data research